Contemporary Therapy for HL: Where Are We Now?
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: October 16, 2015
Expiration Date: October 16, 2016
Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity has been designed to offer you the latest therapeutic insights for the management of Hodgkin lymphoma (HL) from current practice to the status of ongoing clinical trials. As participants, you will have the opportunity to share your professional experiences with us and engage in discussion related to current and future management of this disease.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.
Upon completion of this educational activity, participants should be able to:
- Summarize clinical considerations in the upfront treatment of Hodgkin lymphoma variations in options and standards of care
- Identify current approaches to the treatment of relapsed/refractory HL and evolving approaches in ongoing clinical trials
- Identify key data from ongoing trials in the spectrum of HL disease
Introduction – Franco Cavalli, MD, FRCP
Optimal Treatment Approaches to Frontline Treatment of Hodgkin Lymphoma – Tim Illidge, PhD, MRCP, FRCR, FRCPath
Relapsed/Refractory Hodgkin Lymphoma: Changing Treatment Paradigms? – Peter Borchmann, MD
Instructions for Participation and Credit
This activity is eligible for credit through October 16, 2016. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Franco Cavalli, MD, FRCP
Oncology Institute of Southern Switzerland (IOSI)
Dr. Franco Cavalli is scientific director of the Oncology Institute of Southern Switzerland (IOSI) which has its main location in Bellinzona (Switzerland), but connects all the public hospitals of the Italian speaking part of Switzerland. He created this institute which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology, as well as an important research division. Dr. Cavalli is professor (Titularprofessor) of medical oncology at the Medical Faculty in Bern (Switzerland). He has an international reputation for the treatment of and research into malignant lymphoma and new drugs. Every second year he organizes in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on this topic worldwide. He has been very active also in the field of the clinical evaluation of new drugs. Dr. Cavalli was chairman of the Early Clinical Trials Group of EORTC and created the SENDO (Southern Europe New Drug Organization), a conglomerate which included IOSI and the main cancer institutes in Milan.
Dr. Cavalli is chairman of the Scientific Committee of the European School of Oncology (ESO), and has been president of the Swiss Cancer League, the World Oncology Forum (WOF), and the International Union Against Cancer (UICC). He was also a member of the Swiss Parliament. The quality of his work has been recognized by 24 national and international awards, including the Petzcoller Award for special dedication to oncology and the ESMO Lifetime Achievement Award. He has published more than 500 articles in peer-reviewed journals and has contributed to many books on cancer, including the Textbook of Medical Oncology. He was founding editor and editor-in-chief of Annals of Oncology, Europe’s premier medical oncology journal, and he is on the editorial board of several other journals. In addition, he founded the International Extranodal Lymphoma Study Group (IELSG, www.ielsg.org), which now encompasses more than 200 institutions in four continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas.
Tim Illidge, PhD, MRCP, FRCR, FRCPath
Professor of Targeted Therapy and Oncology
Institute of Cancer Sciences
The University of Manchester
Manchester, United Kingdom
Dr. Tim Illidge completed his undergraduate degree in biochemistry (BSc) at London University, received his medical degree from Guy’s Hospital Medical School, London, and subsequently was awarded a PhD from the University of Southampton for his work in the field of antibody targeting in lymphoma. He completed research fellowships as CRUK senior clinical research fellow and was appointed senior lecturer and honorary consultant in oncology at Southampton University Hospitals NHS Trust. Dr. Illidge was awarded a US senior Fulbright fellowship and a Winston Churchill fellowship which enabled him to work as part of the lymphoma team at Stanford University, California. He later moved his research group to Manchester University based on the Christie Hospital site. Dr. Illidge is currently professor of targeted therapy and oncology at the Institute of Cancer Sciences, University of Manchester.
Dr. Illidge’s clinical interest is lymphoma where he has published extensively including many early phase and late clinical trials, focused on antibodies, antibody drug conjugates, radioimmunotherapy and response adjusted therapy in lymphoma.
Peter Borchmann, MD
Assistant Medical Director
Department of Hematology/Oncology
University Hospital of Cologne
Dr. Peter Borchmann is assistant medical director in the Department of Hematology/Oncology at the University Hospital of Cologne where he is head of the lymphoma program. He is also study secretary of the German Hodgkin Study Group (GHSG) and responsible for development and investigator initiated clinical studies in Hodgkin lymphoma (HL). Dr. Borchmann’s scientific focus within the GHSG is to optimize the treatment of advanced stage HL patients and elderly patients. He is also the leader of the working group “Survivorship” (http://www.ghsg.org).
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-046-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 15-046-017
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Franco Cavalli has received honoraria related to formal advisory activities from Gilead and Novartis AG. He has received grant support related to research activities from F. Hoffmann-La Roche Ltd.
Dr. Tim Illidge has received honoraria related to formal advisory activities from Seattle Genetics, Inc., and speakers’ bureau activities from F. Hoffmann-La Roche Ltd. and Takeda Oncology. He has received grant support related to research activities from Takeda Oncology.
Dr. Peter Borchmann has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Cavalli and Dr. Borchmann have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Illidge has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Cavalli and Dr. Borchmann have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Illidge has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Seattle Genetics, Inc. MediCom Worldwide, Inc. acknowledges support from The Leukemia & Lymphoma Society
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.